Merck & Co., Inc.
Merck & Co., Inc. (MRK) Financial Performance & Income Statement Overview
Analyze Merck & Co., Inc. (MRK) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Merck & Co., Inc. (MRK) Income Statement & Financial Overview
View the income breakdown for Merck & Co., Inc. MRK across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $15.53B | $15.62B | $16.66B | $16.11B |
| Cost of Revenue | $3.42B | $924.00M | $4.08B | $3.75B |
| Gross Profit | $12.11B | $14.70B | $12.58B | $12.37B |
| Gross Profit Ratio | $0.78 | $0.94 | $0.76 | $0.77 |
| R&D Expenses | $3.62B | $4.58B | $5.86B | $3.50B |
| SG&A Expenses | $2.55B | $3.30B | $2.73B | $2.74B |
| Operating Expenses | $6.17B | $7.88B | $8.59B | $6.24B |
| Total Costs & Expenses | $9.59B | $8.80B | $12.67B | $9.98B |
| Interest Income | $0.00 | $146.00M | $127.00M | $69.00M |
| Interest Expense | $0.00 | $328.00M | $330.00M | $310.00M |
| Depreciation & Amortization | $1.41B | $872.67M | $1.19B | $1.13B |
| EBITDA | $7.32B | $6.93B | $5.61B | $7.45B |
| EBITDA Ratio | $0.47 | $0.44 | $0.34 | $0.46 |
| Operating Income | $5.94B | $6.82B | $3.98B | $6.13B |
| Operating Income Ratio | $0.38 | $0.44 | $0.24 | $0.38 |
| Other Income/Expenses (Net) | -$34.00M | -$2.65B | $106.00M | -$122.00M |
| Income Before Tax | $5.90B | $4.17B | $4.09B | $6.006B |
| Income Before Tax Ratio | $0.38 | $0.27 | $0.25 | $0.37 |
| Income Tax Expense | $818.00M | $426.00M | $929.00M | $545.00M |
| Net Income | $5.08B | $3.74B | $3.16B | $5.46B |
| Net Income Ratio | $0.33 | $0.24 | $0.19 | $0.34 |
| EPS | $2.01 | $1.47 | $1.24 | $2.15 |
| Diluted EPS | $2.01 | $1.49 | $1.24 | $2.14 |
| Weighted Avg Shares Outstanding | $2.53B | $2.54B | $2.54B | $2.53B |
| Weighted Avg Shares Outstanding (Diluted) | $2.53B | $2.54B | $2.54B | $2.54B |
Over the past four quarters, Merck & Co., Inc. demonstrated steady revenue growth, increasing from $16.11B in Q2 2024 to $15.53B in Q1 2025. Operating income reached $5.94B in Q1 2025, maintaining a consistent 38% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $7.32B, reflecting operational efficiency. Net income rose to $5.08B, with EPS at $2.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan